| Today’s Big NewsJun 10, 2024 |
| By Annalee Armstrong Moderna’s combo flu and COVID-19 vaccine zipped through a late-stage trial this winter, and the results are showing a higher immune response than licensed comparators—including the famed biotech’s own Spikevax. |
|
|
|
By James Waldron Not content with bringing in one of the largest private biotech fundraises of 2024 so far, Alumis has now become the latest drug developer to set its sights on the public markets. |
By James Waldron Skye Bioscience’s share price tumbled in pre-market trading Monday, as the biotech announced a strategic refocus in the wake of a phase 2 trial failure. |
Sponsored by Montgomery County Economic Development Corporation Drive or take the metro in any direction within Montgomery County, Maryland, and you'll come across a life science company responsible for a major innovation. |
|
Tuesday, June 25, 2024 | 11am ET / 8am PT Expanded Access Programs can help deliver life-saving access to critical medications. Join us for a deep dive into the benefits of EAPs in Europe. Learn how to leverage for achieving faster access to the European market, facilitating successful commercialization, and navigating the array of regulations and guidelines. Register now. 
|
|
By Nick Paul Taylor Oculis is forging ahead with its precision medicine approach to treating dry eye disease, outlining plans to finalize a phase 3 study after seeing some signs of efficacy in a subpopulation in its midstage trial. |
By Helen Floersh Against a backdrop of low-volume but growing concerns about bird flu, the National Institutes of Health’s infectious disease arm has laid out its plans to study the virus that causes the illness. |
By Helen Floersh A $30 million, two-year pilot program from the National Institutes of Health will set up clinical research at primary care facilities in communities with underserved patient populations, with the goal of eventually establishing the means to conduct research projects on issues unique to them. |
By Eric Sagonowsky The FDA assigned the subcutaneous Leqembi application a Prescription Drug User Fee Act decision date of January 25, 2025. |
By Fraiser Kansteiner The FDA approved Arexvy for RSV prevention in adults ages 50 to 59 who are at increased risk of developing RSV disease. The green light marks Arexvy’s first new approval since the vaccine’s original nod to prevent lower respiratory tract disease caused by RSV in adults ages 60 and older last May. |
By Conor Hale Medtronic said the problem lies in the on-screen displays of submillimeter-sensitive information such as “distance to target” or “tip stop point,” which guides the depth of a biopsy needle. |
By Zoey Becker Priya Bhambi, 40, pled guilty to wire fraud charges after running a detailed scheme to scam Takeda into paying for non-existent services from a fake consulting firm. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” the Fierce Pharma Marketing team discusses the annual top pharma drug ad spenders special report. |
|
|---|
|
|
|
July 8-9, 2024 | Jersey City, NJ Hear the latest industry trends from leaders in the field, and developed with input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself.
Save $200 when you Register Today! +(1).png)
|
|
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
Whitepaper This detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data. Sponsored by: Privacy Analytics, an IQVIA company |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
+114x60.png)
